Lipella Pharmaceuticals is focused on developing innovative treatments for serious and rare diseases, leveraging its proprietary drug delivery technology. This technology is particularly aimed at addressing conditions affecting mucosal tissues, such as those found in the bladder, urethra, oral cavity, esophagus, and colon. The company is actively engaged in clinical trials for various conditions, including Oral Lichen Planus and hemorrhagic cystitis, and has received Orphan Drug Designation from the FDA for its drug candidates, LP-10 and LP-410. These designations highlight Lipella's commitment to addressing significant unmet medical needs in underserved patient populations.

In addition to its drug development efforts, Lipella maintains a sterile manufacturing facility in Pittsburgh, PA, which supports the production of clinical supplies and research products. The company is also involved in establishing patient registries, such as the Radiation Cystitis Patient Registry, to enhance the understanding of conditions like radiation cystitis and to document patient experiences. This comprehensive approach not only aims to improve treatment options for patients but also seeks to foster partnerships and commercial licensing agreements to expand the reach and impact of its technologies.

United States

Lipella Pharmaceuticals, Inc. is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis. They are a clinical-stage pharmaceutical company with expertise in drug delivery and the treatment of urologic conditions.

Lipella Pharmaceuticals

Company Details